Navigation Links
Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
Date:9/18/2012

BLUE BELL, Pa., Sept. 18, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today  that J. Joseph Kim, Ph.D., President and CEO, will present and participate in a panel at BIOX, Noble Financial Capital Markets' Life Sciences Exposition to be held at the University of Connecticut, Stamford Campus on September 24-25, 2012.

Inovio Presentation
Monday, September 24
3:00 PM ET

Panel Presentation
Monday, September 24
5:55 PM ET
"Innovation in Immunotherapy & Vaccines"

Following the event, a high-definition video webcast of the presentation will be available on Inovio's website. It will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast will be archived on Inovio's website for 90 days following the event.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, our ability to secure new partnerships and collaborations, capital market conditions,the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended June 30, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo:  http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals 267-440-4211 jrichardson@inovio.com


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
4. MD Anderson Cancer Center joins Actinium Pharmaceuticals (API) Multicenter Actimab-A Trial
5. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
6. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
7. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
8. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
9. Epigenomics, Present and Future Applications for Pharmaceuticals and Diagnostics: Twease.org
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2020)... (PRWEB) , ... May 13, 2020 , ... ... reporter assays or phenotypic readouts, providing little or no information on the drug’s ... a more comprehensive characterization of compounds by measuring the activity of molecular pathways. ...
(Date:5/5/2020)... ... May 05, 2020 , ... ProductLife Group has marked the next ... the group after 13 years at Altran, where he was Group VP of Life ... and being a Pharmacist, Xavier was involved in his early career in the development ...
(Date:4/26/2020)... (PRWEB) , ... April 23, 2020 , ... ... Azure Marketplace today, an online store providing applications and services for use on ... certain well-defined business needs to sign up online for a built-for-purpose customer engagement ...
(Date:4/22/2020)... (PRWEB) , ... April 21, 2020 , ... ... FXIII chromogenic method for determination of FXIII. , Aniara Diagnostica, a multi-national distributor ... commitment to meeting today’s highest standards for product quality and cost-efficient delivery. ...
Breaking Biology Technology:
(Date:4/30/2020)... ... 2020 , ... At the start of 2020 ILC ... a wide range of industries including pharmaceutical and biopharmaceutical manufacturing, healthcare, food and ... decade, it was clear to company leadership that they would have to adapt ...
(Date:4/26/2020)... (PRWEB) , ... April 23, 2020 , ... ... specializing in computer miniaturization, backed by FII Tech Growth managed by Fondo Italiano ... in the biomedical market, for the development of Respira, a new non-invasive pulmonary ...
(Date:4/23/2020)... (PRWEB) , ... April 23, 2020 , ... ... expansion and recruitment plans. MDG provides critical infrastructure products for the animal feed, ... MDG’s previous plans for expansion. Further, as supply channels from overseas competitors have ...
Breaking Biology News(10 mins):